Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$216000.0.

  • Maxcyte's Gains from Investment Securities fell 11976.21% to -$216000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 2852.03%. This contributed to the annual value of $14.1 million for FY2024, which is 883.51% down from last year.
  • Maxcyte's Gains from Investment Securities amounted to -$216000.0 in Q3 2025, which was down 11976.21% from $886000.0 recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Gains from Investment Securities peaked at $24.5 million during Q4 2021, and registered a low of -$1.0 million during Q3 2021.
  • Over the past 5 years, Maxcyte's median Gains from Investment Securities value was $269300.0 (recorded in 2022), while the average stood at $2.1 million.
  • Per our database at Business Quant, Maxcyte's Gains from Investment Securities crashed by 113098.59% in 2021 and then soared by 486818.18% in 2024.
  • Quarter analysis of 5 years shows Maxcyte's Gains from Investment Securities stood at $24.5 million in 2021, then tumbled by 81.2% to $4.6 million in 2022, then decreased by 6.67% to $4.3 million in 2023, then plummeted by 37.85% to $2.7 million in 2024, then plummeted by 108.09% to -$216000.0 in 2025.
  • Its Gains from Investment Securities was -$216000.0 in Q3 2025, compared to $886000.0 in Q2 2025 and $254000.0 in Q1 2025.